FiercePharmaOriginal article
{"a":[{"_":"Amgen hands in data package in hopes of FDA hearing for Tavneos defense","$":{"href":"/pharma/amgen-hands-data-package-hopes-fda-hearing-tavneos-defense","hreflang":"en"}}]}
RegulatoryTavneosNeutral
AI Analysis
Summary
Amgen submitted a data package to the FDA in an attempt to schedule a hearing to defend the approval status of Tavneos, an ANCA-associated vasculitis drug acquired through its $3.7 billion ChemoCentryx acquisition, which faces uncertain regulatory status.
Outcome Details
Amgen submitted data package for FDA hearing regarding Tavneos approval status
Importance:7/10
Sentiment:
0.00
FDAregulatorydrug approvalacquisitionTavneosvasculitis
Related Companies
Read the original article
Published by FiercePharma on July 24, 2026 10:22 AM